JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nieuwlaat, W.-A.
Right arrow Articles by Huysmans, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nieuwlaat, W.-A.
Right arrow Articles by Huysmans, D. A.

Dosimetry of Radioiodine Therapy in Patients with Nodular Goiter After Pretreatment with a Single, Low Dose of Recombinant Human Thyroid-Stimulating Hormone

Willy-Anne Nieuwlaat, MD1,2, Ad R. Hermus, MD, PhD2, H. Alec Ross, PhD3, Wilhelmina C. Buijs, PhD4, Michela A. Edelbroek, MD1, Jo W. Bus1, Frans H. Corstens, MD, PhD4 and Dyde A. Huysmans, MD, PhD1

1 Department of Nuclear Medicine, Catharina Hospital, Eindhoven, The Netherlands
2 Department of Endocrinology, University Medical Center Nijmegen, Nijmegen, The Netherlands
3 Department of Chemical Endocrinology, University Medical Center Nijmegen, Nijmegen, The Netherlands
4 Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands



View larger version (12K):

[in a new window]
  		FIGURE 1. Total 131I activity and PB131I activity per liter of serum on day 0 after radioiodine therapy in patients with nodular goiter. (A and B) Nine patients were pretreated with 0.01 mg of rhTSH (A), and 9 with 0.03 mg of rhTSH (B). The results for each rhTSH group were compared with those for 9 control patients. Mean value + SEM is given. {blacksquare} = total 131I activity in rhTSH-pretreated patients; {square} = total 131I activity in control patients; • = PB131I activity in rhTSH-pretreated patients; {circ} = PB131I activity in control patients.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2004 by the Society of Nuclear Medicine.